Brain & Nervous System Stroke Diagnosis & Treatment TPA: Tissue Plasminogen Activator for Stroke By Heidi Moawad, MD Heidi Moawad, MD Facebook LinkedIn Heidi Moawad is a neurologist and expert in the field of brain health and neurological disorders. Dr. Moawad regularly writes and edits health and career content for medical books and publications. Learn about our editorial process Updated on April 21, 2021 Medically reviewed Verywell Health articles are reviewed by board-certified physicians and healthcare professionals. These medical reviewers confirm the content is thorough and accurate, reflecting the latest evidence-based research. Content is reviewed before publication and upon substantial updates. Learn more. by Huma Sheikh, MD Medically reviewed by Huma Sheikh, MD Facebook LinkedIn Twitter Huma Sheikh, MD, is a board-certified neurologist, specializing in migraine and stroke, and affiliated with Mount Sinai of New York. Learn about our Medical Expert Board Print Tissue plasminogen activator, most commonly known as TPA, is a powerful blood thinner used for emergency stroke treatment. Approved by the Food and Drug Administration (FDA) in 1996 for the treatment of stroke, it was initially viewed as both revolutionary and risky. Since then, stroke treatment has advanced a lot, but TPA is still the most dramatic improvement to come about in the care of stroke patients. This article will provide information about TPA for emergency stroke treatment. Clerkenwell / Getty Images What Is TPA and Why Is It Used for Strokes? Tissue plasminogen activator is a powerful agent that dissolves blood clots. It is injected by intravenous administration (IV) for emergency stroke treatment. A stroke is caused by an interruption in blood flow either due to a blood clot (ischemic stroke) or a bleed (hemorrhagic stroke) in the brain. TPA is only used for strokes caused by blood clots. When TPA is injected into a vein, it quickly travels through the blood to reach the clogged blood vessel, where it works by trying to dissolve the blood clot and to restore blood flow to the brain. This allows the brain to remain healthy before stroke damage can occur. Can You Ask for TPA? Intravenous TPA has to be administered within the first few hours after a stroke begins. The start of a stroke is counted from the time that you first notice stroke symptoms. After this very short window of a few hours after a stroke starts, you cannot receive TPA because it might cause more harm than good at that point. Clinical Guidelines for the Use of TPA Clinical guidelines for the early treatment of stroke published jointly by the American Heart Association and American Stroke Association strongly recommend the use of TPA for eligible patients within three hours of symptom onset. Some of the eligibility criteria involved in the decision to use TPA include other heart conditions, blood glucose levels, blood pressure levels, and age. Most of the time, patients do not ask for TPA. But emergency medical workers are trained to recognize a stroke and emergency rooms are equipped with the staff and provisions to administer TPA when it is necessary. Does TPA Help Strokes? Since its inception, TPA has been administered to many patients. The long-term and short-term effects of TPA have been carefully evaluated. Overall, in the right circumstances, TPA has been proven to be beneficial. A comparison of stroke patients who did receive TPA vs. stroke patients who did not receive TPA showed that the group of patients who were treated with TPA experienced better physical function, better cognitive abilities, and better survival rates than the stroke patients who did not get the TPA treatment. The sooner stroke patients receive TPA, the better the recovery. For every 15-minute delay in TPA treatment, the poorer the outcome. In fact, a national quality improvement initiative aimed at reducing the waiting time for TPA administration improved patients’ survival and decreased complications of TPA treatment. Mobile stroke units in some cities can help stroke patients receive treatment faster. Complications of TPA Because TPA is a powerful blood thinner, the main side effect is bleeding. Bleeding is a serious complication that can result in a hemorrhagic stroke, which is often more serious than an ischemic stroke. Additionally, TPA can cause stomach bleeding, intestinal bleeding, bleeding in the urine, or bleeding of healing wounds or surgical incisions. For these reasons, some patients are not candidates for TPA. TPA is very fast acting, and its effect does not last very long. If you receive TPA and do not experience any side effects or complications within the first few days, you do not need to be concerned about delayed or long-term side effects from TPA during your recovery or after you go home. A Word From Verywell TPA is an important stroke treatment that can save your life. However, it can be dangerous and not everyone is a safe candidate for TPA. Also, if the narrow window of time to safely use TPA has elapsed by the time you reach the hospital, you cannot receive intravenous TPA treatment. It is only beneficial if it is given within the first few hours after a stroke has started. 5 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Tsivgoulis G, Safouris A, Alexandrov AV. Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions. Expert Opin Drug Saf. 2015;14(6):845-864. doi:10.1517/14740338.2015.1032242 Lang CE, Bland MD, Cheng N, Corbetta M, Lee JM. A case-control study of the effectiveness of tissue plasminogen activator on 6 month patients--reported outcomes and health care utilization. J Stroke Cerebrovasc Dis. 2014;23(10):2914-2919. doi:10.1016/j.jstrokecerebrovasdis.2014.07.049 Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488. doi:10.1001/jama.2013.6959 Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311(16):1632-1640. doi:10.1001/jama.2014.3203 By Heidi Moawad, MD Heidi Moawad is a neurologist and expert in the field of brain health and neurological disorders. Dr. Moawad regularly writes and edits health and career content for medical books and publications. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit